Last updated: April 23, 2026
What is PL2421522 and what does it protect?
PL2421522 is a Poland national patent publication (publication/filing identifier) covering a pharmaceutical invention with claims directed to a specific drug substance and/or its pharmaceutical composition(s), along with method-of-treatment and/or formulation/usage positions typical for therapeutic filings in Poland.
Core scope pattern (typical claim architecture for PL2421522-style pharmaceutical national phase filings):
- Product scope: drug substance and/or defined chemical entity (structure-defined or formula-defined).
- Composition scope: pharmaceutical composition with defined excipients or formulation parameters.
- Use scope: treatment of a defined disease/indication set.
- Method scope: method of treatment using the claimed drug/composition.
What does the claim set likely look like (and what is enforceable scope)?
A full, claim-by-claim construction requires the exact text of the issued/active claims. Sufficient claim text is not present in the information available in this conversation, so a complete and accurate claim map cannot be produced.
That said, the enforceable scope in Poland for this class of filings generally falls into one of the following buckets, depending on claim numbering and dependency structure:
- Independent claim to the compound (chemical scope)
- Claim defines the compound by formula/structure and/or parameterized definition (substituent set, stereochemistry, salt form).
- Independent claim to the composition (formulation scope)
- Claim defines a pharmaceutical composition including the compound plus excipients, sometimes with constraints (dose range, release profile, particle size, solubility parameters).
- Independent claim to use (indication scope)
- Claim defines a medical use for the compound in treating a listed condition.
- Independent claim to method of treatment (process scope)
- Claim defines a regimen (dose, schedule, patient selection), with dependencies tightening the regimen.
How broad is the protection in practice?
For Poland, practical breadth is driven by:
- Definition type: broad formula ranges vs narrowly enumerated embodiments.
- Salt/polymorph coverage: whether claims extend to salts, solvates, polymorphs, stereoisomers.
- Indication specificity: whether claims cover multiple disease states or a single indication.
- Formulation constraints: whether composition claims are constrained to specific excipients/delivery systems.
A complete breadth assessment requires the exact claim language. Without the claim text, any attempt to state breadth would not be complete or accurate.
What is the patent landscape around PL2421522 in Poland (generics and adjacent rights)?
A robust landscape needs:
- the exact active ingredient / INN (or chemical name) covered by PL2421522,
- the publication and family members (WO/EP/US counterparts),
- the status of each family member in Poland (granted/pending, term, oppositions),
- any supplementary protection certificates (SPCs) listed for the drug in Poland,
- and the existence of process or formulation patents that create additional barriers.
This cannot be produced accurately from the current conversation because the protected drug identity and claim set are not provided.
What dates control expiration and freedom-to-operate in Poland?
For pharmaceutical rights in Poland, expirations commonly flow from:
- priority date (earliest priority in the family),
- filing and grant timeline (20-year term from filing, subject to adjustments),
- SPC timelines (if an SPC is granted based on first marketing authorization),
- and regulatory exclusivities (where applicable).
A time-to-expiry table requires the actual priority/filing/authorization data for the underlying active ingredient in this specific case. Those data are not available in the current input.
Key Takeaways
- PL2421522’s enforceable scope cannot be mapped claim-by-claim from the information available in this conversation.
- A complete Poland landscape for generics vs branded vs formulation/process blockers requires the exact drug identity, claim text, and family status for PL2421522.
- No reliable expiration/SPC timeline can be stated without the underlying priority and authorization/SPC records tied to this patent.
FAQs
- What claim elements usually define product vs method protection for Polish pharmaceutical patents?
- How do SPCs in Poland change the practical expiration of a compound patent family?
- What typically limits composition claim breadth in Poland (excipients, dose, release profile)?
- How do dependent claims affect infringement risk for generics manufacturing at design-around doses?
- What filings most often appear as “adjacent rights” in the same therapeutic space in Poland?
References
[1] European Patent Register (EPO) - INPADOC family and publication data for related filings. https://register.epo.org/
[2] Patent information for Poland from the Polish Patent Office (UPRP) / Espacenet entry points. https://pl.espacenet.com/
